Alexion gets EmblemHealth's US antitrust case over Soliris dismissed in part
MLex Summary: A Massachusetts federal judge has granted in part Alexion Pharmaceuticals' motion to dismiss a US antitrust complaint brought by EmblemHealth, which alleged Alexion unlawfully delayed biosimilar competition for its...To view the full article, register now.
Already a subscriber? Click here to view full article